

Ian Smith

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11524689/publications.pdf>

Version: 2024-02-01

46
papers

21,656
citations

185998

28
h-index

264894

42
g-index

48
all docs

48
docs citations

48
times ranked

24137
citing authors

#	ARTICLE	IF	CITATIONS
1	Abstract PD15-02: HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer. <i>Cancer Research</i> , 2022, 82, PD15-02-PD15-02.	0.4	0
2	Abstract PS18-10: Intratumoural heterogeneity in PgR expression: Molecular and prognostic significance. , 2021, , .		0
3	Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients. <i>Breast Cancer Research</i> , 2020, 22, 2.	2.2	15
4	Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2019, 111, 86-94.	3.0	73
5	Long-term outcome with targeted therapy in advanced/metastatic HER2-positive breast cancer: The Royal Marsden experience. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 401-408.	1.1	14
6	Genomic Instability and TP53 Genomic Alterations Associate With Poor Antiproliferative Response and Intrinsic Resistance to Aromatase Inhibitor Treatment. <i>JCO Precision Oncology</i> , 2019, 3, 1-11.	1.5	0
7	Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial. <i>Anticancer Research</i> , 2019, 39, 797-802.	0.5	0
8	Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations. <i>British Journal of Cancer</i> , 2019, 120, 247-255.	2.9	13
9	Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 249-258.	1.1	6
10	Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor-Positive Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky005.	1.4	11
11	Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1041-1048.	0.8	87
12	11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. <i>Lancet, The</i> , 2017, 389, 1195-1205.	6.3	770
13	Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 1179-1188.	0.8	91
14	Evaluation of RNAi and CRISPR technologies by large-scale gene expression profiling in the Connectivity Map. <i>PLoS Biology</i> , 2017, 15, e2003213.	2.6	136
15	Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence. <i>Journal of Clinical Oncology</i> , 2016, 34, 2452-2459.	0.8	178
16	Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation. <i>Nature Communications</i> , 2016, 7, 13294.	5.8	34
17	Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas. <i>Breast Cancer Research</i> , 2016, 18, 39.	2.2	24
18	Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 127-132.	1.1	7

#	ARTICLE	IF	CITATIONS
19	Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. <i>Nature Biotechnology</i> , 2016, 34, 184-191.	9.4	3,168
20	Risk of recurrence estimates with IHC4+C are tolerant of variations in staining and scoring: an analytical validity study. <i>Journal of Clinical Pathology</i> , 2016, 69, 128-135.	1.0	12
21	Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 1034-1042.	0.8	315
22	Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. <i>Annals of Oncology</i> , 2015, 26, 1533-1546.	0.6	1,449
23	A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: An analysis of the ATHENA trial. <i>Breast</i> , 2014, 23, 656-662.	0.9	42
24	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. <i>Lancet Oncology</i> , The, 2014, 15, 1137-1146.	5.1	382
25	Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. <i>Nature Biotechnology</i> , 2014, 32, 1262-1267.	9.4	1,351
26	2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. <i>Lancet</i> , The, 2013, 382, 1021-1028.	6.3	447
27	Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. <i>Annals of Oncology</i> , 2013, 24, 2206-2223.	0.6	2,805
28	Magnitude of Trastuzumab Benefit in Patients With HER2-Positive, Invasive Lobular Breast Carcinoma: Results From the HERA Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 1954-1960.	0.8	39
29	Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 1191-1198.	1.1	36
30	The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 295-306.	1.1	11
31	Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. <i>Lancet Oncology</i> , The, 2011, 12, 236-244.	5.1	575
32	Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. <i>Lancet Oncology</i> , The, 2011, 12, 1101-1108.	5.1	356
33	Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?. <i>Breast</i> , 2011, 20, S158-S161.	0.9	16
34	Final overall survival results and effect of prolonged (1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 133-143.	1.1	52
35	Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 1117-1124.	0.8	134
36	Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer. <i>New England Journal of Medicine</i> , 2009, 361, 766-776.	13.9	448

#	ARTICLE	IF	CITATIONS
37	Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. <i>Lancet, The</i> , 2009, 373, 1681-1692.	6.3	168
38	Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIC 1-98. <i>Journal of Clinical Oncology</i> , 2007, 25, 486-492.	0.8	835
39	2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. <i>Lancet, The</i> , 2007, 369, 29-36.	6.3	1,361
40	Medical treatment of early breast cancer. I: adjuvant treatment. <i>BMJ: British Medical Journal</i> , 2006, 332, 34-37.	2.4	15
41	Goals of Treatment for Patients With Metastatic Breast Cancer. <i>Seminars in Oncology</i> , 2006, 33, 2-5.	0.8	59
42	Medical treatment of early breast cancer. II: endocrine therapy. <i>BMJ: British Medical Journal</i> , 2006, 332, 101-103.	2.4	4
43	Medical treatment of early breast cancer. III: chemotherapy. <i>BMJ: British Medical Journal</i> , 2006, 332, 161-162.	2.4	7
44	Medical treatment of early breast cancer. IV: neoadjuvant treatment. <i>BMJ: British Medical Journal</i> , 2006, 332, 223-224.	2.4	21
45	A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer. <i>New England Journal of Medicine</i> , 2005, 353, 2747-2757.	13.9	1,465
46	Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2005, 353, 1659-1672.	13.9	4,601